Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetes

References

• Jain R. Utility of saxagliptin in the treatment of type 2 diabetes: review of efficacy and safety. Adv Ther. 2015;32:1065–1084.
   PubMed Web of Science ®Google Scholar
• Dhillon S. Saxagliptin: A review in type 2 diabetes. Drugs. 2015;75:1783–1796.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Aguilar-Salinas C, Klein E, et al. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin. 2009;25:2401–11.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009;32:1649–1655.
   PubMed Web of Science ®Google Scholar
• Pfutzner A, Paz-Pacheco E, Allen E, et al. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes Obes Metab. 2011;13:567–576.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment. Expert Opin Drug Metab Toxicol. 2012;8:383–394.
   PubMed Web of Science ®Google Scholar
• Hollander P, Li J, Allen E, et al. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab. 2009;94:4810–4819.
   PubMed Web of Science ®Google Scholar
• Chacra AR, Tan GH, Ravichandran S, et al. Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks. Diab Vasc Dis Res. 2011;8:150–159.
   PubMed Web of Science ®Google Scholar
• Barnett AH, Charbonnel B, Donovan M, et al. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin. 2012;28:513–523.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Hansen L, Zee P, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015;38:376–83.
   PubMed Web of Science ®Google Scholar
• Cole PSN, Serradell N, Bolos J, et al. Saxagliptin. Drugs Future. 2008;33(7):577–586.
   Web of Science ®Google Scholar
• Augeri DJ, Robl JA, Betebenner DA, et al. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem. 2005;48:5025–5037.
   PubMed Web of Science ®Google Scholar
• Boulton DW, Li L, Frevert EU, et al. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin Pharmacokinet. 2011;50:253–65.
   PubMed Web of Science ®Google Scholar
• Nowicki M, Rychlik I, Haller H, et al. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract. 2011;65:1230–1239.
   PubMed Web of Science ®Google Scholar
• Barnett AH, Charbonnel B, Li J, et al. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy. Clin Drug Investig. 2013;33:707–717.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–1326.
   PubMed Web of Science ®Google Scholar
• Dhillon S, Weber J. Saxagliptin. Drugs. 2009;69:2103–2114.
   PubMed Web of Science ®Google Scholar
• Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012;51:501–514.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opin Drug Saf. 2015;14:505–524.
   PubMed Web of Science ®Google Scholar
• Fura A, Khanna A, Vyas V, et al. Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections. Drug Metab Dispos. 2009;37:1164–1171.
   PubMed Web of Science ®Google Scholar
• Patel CG, Kornhauser D, Vachharajani N, et al. Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects. Diabetes Obes Metab. 2011;13:604–614.
   PubMed Web of Science ®Google Scholar
• Tahrani AA, Piya MK, Barnett AH. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Adv Ther. 2009;26:249–262.
   PubMed Web of Science ®Google Scholar
• Ali S, Fonseca V. Saxagliptin overview: special focus on safety and adverse effects. Expert Opin Drug Saf. 2013;12:103–109.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes. Clin Pharmacokinet. 2015;54:1–21.
   PubMed Web of Science ®Google Scholar
• Ramirez G, Morrison AD, Bittle PA. Clinical practice considerations and review of the literature for the Use of DPP-4 inhibitors in patients with type 2 diabetes and chronic kidney disease. Endocr Pract. 2013;19:1025–1034.
   PubMed Web of Science ®Google Scholar
• Udell JA, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Diabetes Care. 2015;38:696–705.
   PubMed Web of Science ®Google Scholar
• Nowicki M, Rychlik I, Haller H, et al. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab. 2011;13:523–532.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet. 2010;49:573–588.
   PubMed Web of Science ®Google Scholar
• Mudaliar S. Choice of early treatment regimen and impact on beta-cell preservation in type 2 diabetes. Int J Clin Pract. 2013;67:876–887.
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Charpentier G, Ostgren CJ, et al. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2010;26:540–549.
   PubMed Web of Science ®Google Scholar
• Moses RG, Kalra S, Brook D, et al. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea. Diabetes Obes Metab. 2014;16:443–450.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Metformin + saxagliptin for type 2 diabetes. Expert Opin Pharmaco. 2012;13:139–146.
   PubMed Web of Science ®Google Scholar
• Goke B, Gallwitz B, Eriksson J, et al. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract. 2010;64:1619–1631.
   PubMed Web of Science ®Google Scholar
• Williams DM, Stephens JW. Combination therapy with saxagliptin and dapagliflozin for the treatment of type 2 diabetes. Expert Opin Pharmaco. 2015;16:2373–2379.
   PubMed Web of Science ®Google Scholar
• Yagi S, Aihara K, Akaike M, et al. Predictive factors for efficacy of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus. Diabetes Metab J. 2015;39:342–347.
   PubMed Web of Science ®Google Scholar
• Esposito K, Chiodini P, Maiorino MI, et al. A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients. BMJ Open. 2015;5:e005892.
   PubMed Web of Science ®Google Scholar
• Gross JL, Rogers J, Polhamus D, et al. A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus. BMJ Open. 2013;3:e001844–e001844.
   Web of Science ®Google Scholar
• Schernthaner G, Duran-Garcia S, Hanefeld M, et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes Obes Metab. 2015;17:630–638.
   PubMed Web of Science ®Google Scholar
• Davidson JA. Tolerability of saxagliptin in patients with inadequately controlled type 2 diabetes: results from 6 phase III studies. Journal Managed Care Pharmacy: JMCP. 2014;20:120–129.
   PubMed Web of Science ®Google Scholar
• Frederich R, Alexander JH, Fiedorek FT, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med. 2010;122:16–27.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130:1579–88.
   PubMed Web of Science ®Google Scholar
• Iqbal N, Parker A, Frederich R, et al. Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials. Cardiovasc Diabetol. 2014;13:33.
   PubMed Web of Science ®Google Scholar
• Iqbal N, Allen E, Öhman P. Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged ≥ 65 years) with type 2 diabetes. Clin Interv Aging. 2014;9:1479–1487.
   Google Scholar
• Giorda CB, Sacerdote C, Nada E, et al. Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies. Endocrine. 2015;48:461–471.
   PubMed Web of Science ®Google Scholar
• Raz I, Bhatt DL, Hirshberg B, et al. Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin. Diabetes Care. 2014;37:2435–2441.
   PubMed Web of Science ®Google Scholar
• Leiter LA, Teoh H, Mosenzon O, et al. Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial. Diabetes Obes Metab. 2016;18:186–190.
   PubMed Web of Science ®Google Scholar
• Bryzinski B, Allen E, Cook W, et al. Saxagliptin efficacy and safety in patients with type 2 diabetes receiving concomitant statin therapy. J Diabetes Complications. 2014;28:887–893.
   PubMed Web of Science ®Google Scholar